Avara Pharmaceutical Services Celebrates One Year Since Launch With Arecibo (PR) Site and Acquisition of Shannon, Ireland Site
Created in 2015, Avara Pharmaceutical Services is a state-of-the-art contract development and manufacturing organization (CDMO) providing both primary formulation and manufacturing, and secondary manufacturing and packaging of small molecules.
NORWALK, Conn., Sept. 19, 2016
NORWALK, Conn., Sept. 19, 2016 /PRNewswire/ — Avara Pharmaceutical Services, Inc. (“Avara”) recently celebrated their first year since the acquisition of their Arecibo, Puerto Rico, site from Merck. Since that time, Avara, headquartered in Norwalk, CT, (USA), now has four manufacturing facilities with about 800 employees in 4 countries.
Most recently, Avara announced the acquisition of the AstraZeneca manufacturing facility located in Avlon, Avonmouth, England. The active pharmaceutical ingredient (API) formulation and manufacturing capabilities in Avlon complement the existing API operation in Shannon, Ireland. The Shannon, Ireland facility was acquired from UCB earlier in 2016 and is also an API site.
Avara also recently announced the acquisition from Astellas of their Norman, Oklahoma secondary manufacturing and packaging facility, which complemented the secondary manufacturing and packaging capabilities of Arecibo, which include state-of-the-art manufacturing facilities for secondary formulation, manufacturing and packaging.
Created in 2015, Avara Pharmaceutical Services is a state-of-the-art contract manufacturing and technical services organization providing both API formulation and manufacturing and secondary manufacturing and packaging of small molecule drugs, including highly potent compounds. Their secondary manufacturing technologies include granulation, coating, blending, encapsulation, compression and drying of tablets and capsules.
Avara Pharmaceutical Services now has five sites. Two in the US, including our corporate HQs; one in Puerto Rico one in the UK and one in Ireland.
- Norwalk, CT (USA) – Corporate HQ
- Arecibo, Puerto Rico – Acquired from Merck: Secondary manufacturing and packaging
- Shannon, Ireland – Acquired from UCB: API manufacturing
- Norman, OK (USA) – Acquired from Astellas: Secondary manufacturing and packaging
- Avlon, United Kingdom – Acquired from Astra Zeneca-API
“As we celebrate these key milestones, we continue with great confidence to build a pharmaceutical services company with complementary offerings in key regions in this rapidly growing market. Each site has significant professional experience, state of the art capabilities and a long history of delivering high quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements in every major market around the world. The people that are a part of the Avara team are the key to our long term success,” said Tim Tyson, Chairman and CEO of Avara. “Our rapid growth has been facilitated by expert counsel and support from Results International and Skadden, Arps, Slate, Meagher and Flom.”
Avara Pharmaceutical Services, Inc., based in Norwalk, Connecticut is an international pharmaceutical services company that delivers world-class contract manufacturing and technical services to the pharmaceutical industry. Avara has primary and secondary manufacturing facilities in North America and Europe and supplies products to all major markets around the world. Our broad experience with supply chain, commercialization, product launch and product transfer allows us to sustain exemplary levels of product quality and regulatory compliance. We are known to exceed customer service level expectations and consistently deliver on time, in full at a fair price. For more information, please visit our website at www.avara.com
Media Contact: Guy Tiene, firstname.lastname@example.org, 212-366-4455
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avara-pharmaceutical-services-celebrates-one-year-since-launch-with-arecibo-pr-site-and-acquisition-of-shannon-ireland-site-300329815.html
SOURCE Avara Pharmaceutical Services, Inc.